10. Have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication, Pembrolizumab (Cycle 1, Day 1) (female subjects of childbearing potential). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.